ALS treatments

Dr. Angela Genge
Director – ALS Center of Excellence
Montreal Neurological Institute and Hospital
CMO Quralis

Disclosures

- Quralis
- AL-S Pharma
- Amylyx
- Cytokinetics
- Mitsubishi Tanabe Pharma
- Biogen
- Alexion
- Eli Lilly
- Sanofi Genzyme
- ALS Canada Board member
- Calico

ALS Treatments

Learning Objectives

- Currently approved therapies in different regions
- Role of multidisciplinary care in ALS
- Future of genetic based therapies in ALS

At the end of this session the attendees will have a review of currently approved therapies and major advances in ALS treatments

Current Development Pipeline in ALS



Source: GlobalData

Note: The innermost circle represents drugs in Phase III development. The circle in the middle represents drugs in Phase II and Phase I/II development. The outermost circle represents drugs in Phase I development.

Riluzole Pivotal Clinical Trials

- Riluzole is believed to function by altering glutamate release and uptake[1,2]
- Two randomized, double-blind, placebo-controlled studies[1,2]
- Both showed statistically significantly greater survival with riluzole vs placebo[1,2]
- The differences in median survival were 90 days in the first study and 60 days in the second study[1,2]
- A meta analysis however suggests the benefit may be up to 18 months

ALS Riluzole Study Group[1]



ALS Riluzole Study Group II[2]



1. Bensimon, G, et al. *N Engl J Med.* 1994;330(9):585-591.
2. Lacomblez, L, et al. *Lancet.* 1996;347(9013):1425-1431.

Oral Edaravone Study A01 Results

- In general, investigational oral edaravone was well tolerated during the study[1]
- No serious TEAEs were related to study drug[1]
- Many of the TEAEs were representative of ALS progression[1]
- Edaravone slows progression but is not a cure for ALS, therefore some ALS progression during the study is expected[1]
- Safety results were generally consistent with the IV edaravone safety profile[1]
- No new safety concerns were identified during this study[1]
- FVC decline and ALSFRS-R score decline were comparable with the edaravone arm in the IV edaravone pivotal phase 3 trial, Study 19[2]

FVC, forced vital capacity; TEAE, treatment-emergent adverse event.

1. Genge A, et al. 24-week results from the MT-1186-A01 phase 3, open-label, multicenter safety study of oral edaravone in subjects with amyotrophic lateral sclerosis. Presented at: 32nd International Symposium on ALS/MND; December 7-10, 2021. Poster CLT-23.
2. Writing Group; Edaravone (MCI-186) ALS 19 Study Group. *Lancet Neurol.* 2017;16(7):505-512.

Tofersen/Qalsody – Clinical development plan



Key biomarkers:

- Reduction in SOD1 protein
- Neurofilament light (NfL)

Key clinical outcomes:

- ALSFRS-R
- SVC
- HHD
- PROs
- Time to event

Clinicaltrials.gov - NCT02623699; NCT03070119